{"schema_version":"secwatch.filing_event.v1","accession":"0000816956-26-000051","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.784530+00:00","generated_at":"2026-05-15T02:35:41.020591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance","bullets":["Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.","GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.","FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.","Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.","GI product exit impacted sales by $15.5M; company focusing on higher-growth areas."],"urls":{"canonical":"https://secwatch.observer/filing/0000816956-26-000051","json":"https://secwatch.observer/filing/0000816956-26-000051.json","markdown":"https://secwatch.observer/filing/0000816956-26-000051.md","text":"https://secwatch.observer/filing/0000816956-26-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/cnmd-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:35:41.020591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bb9a32add6154903dabbdfd7d454bce90ec5a1d","claim":"CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.","evidence_excerpt":"The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2026"},{"label":"EPS","value":"$4.30 to $4.45"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"9bb9a32add6154903dabbdfd7d454bce90ec5a1d","claim":"CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.","evidence_excerpt":"The Company continues to expect full-year adjusted diluted net earnings per share (2) in the range of $4.30 to $4.45.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2026"},{"label":"EPS","value":"$4.30 to $4.45"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ba8974c4cf07466cece1639c064f54164154f6c4","claim":"CONMED Corp reported Q1 2026 results: EPS $0.89.","evidence_excerpt":"Adjusted diluted net earnings per share (1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000051/0000816956-26-000051-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"EPS","value":"$0.89"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}